Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 2, 2014

View Archived Issues

ADN-3662 demonstrates activity in well-recognized in vivo models of mood deficits

New mTOR inhibitors discovered at Sanofi

Preclinical profile of basimglurant described

Atox Bio awarded BARDA contract for development of AB-103

Phase IIa topline results for dupilumab in patients with chronic sinusitis with nasal polyps

Tonix reports topline data from BESTFIT study of TNX-102 SL for fibromyalgia

Helix BioPharma reports interim data from phase I/II trial of L-DOS-47

Sarepta Therapeutics reports favorable data from phase I trial of antisense therapy for influenza

Lumara Health to be acquired by Amag Pharmaceuticals, sells women's health assets to Perrigo

Dimerix Bioscience receives approval to begin phase II trial of DMX-200

Phase II data presented in patients with CMV and adenovirus resistance profiles

Model of autoimmune optic neuritis used to assess new treatment strategy

Novel candidates for neuropathic pain prepared at Nippon Chemiphar

Novel fusion proteins patented by Pfizer as N. meningitidis vaccines

Merck KGaA divulges novel GCN2 inhibitors

Gedeon Richter presents new histamine H3 receptor antagonists

New LRRK2 inhibitors disclosed by Merck & Co.

Epigen Biosciences discloses novel LPA-1 receptors

Reata cleared to run phase II studies of RTA-408 in Friedreich's ataxia and mitochondrial myopathies

Kamada confirms second extension of strategic agreement with Baxter

Compugen reports new results for CGEN-15049 target candidate

Portola reports successful outcome from first phase III study of andexanet alfa

Enanta regains full rights from Novartis to EDP-239 for HCV

Zafgen begins phase III trial of beloranib in Prader-Willi syndrome

OnCore Biopharma to acquire Enantigen Therapeutics

Alnylam initiates observational EXPLORE study in hepatic porphyrias

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 18, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 18, 2025.
Maintenance, man: Lilly’s phase III weight trial hits goals
BioWorld
Eli Lilly and Co. took another step toward adding a way for patients to hang onto their weight loss when the firm disclosed positive top-line data from the phase...
AI drug developer Insilico to raise $292 million in Hong Kong IPO
BioWorld
Insilico Medicine Inc. plans to raise HK$2.27 billion (US$292 million) in its IPO on the Hong Kong Securities Exchange to advance its clinical pipeline and invest...